Mesoblast vs Regenxbio
MESO and RGNX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MESO and RGNX compare
Mesoblast grew revenue faster over the last twelve months (599% versus 12.0% for Regenxbio).
Mesoblast keeps more of each dollar of sales as profit, with a net margin of −47.8% compared with −113% at Regenxbio.
Mesoblast scores higher on the StockData Score (6 against 4 for Regenxbio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MESO | RGNX |
|---|---|---|
| Size and price | ||
| Market cap | – | $504M |
| Share price | $13.27 | $7.64 |
| Change, 1 year | −15.5% | −34.1% |
| Change, 5 years | 6.3% | −77.2% |
| Beta (5Y) | 1.50 | 1.78 |
| Employees | 108 | 371 |
| StockData Score | ||
| Total score | 6 (better) | 4 |
| Valuation score | 0 | 0 |
| Growth score | 3 (better) | 2 |
| Performance score | 2 (better) | 1 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 2.9× |
| P/B | – | 7.0× |
| FCF yield | – | −49.5% |
| Growth | ||
| Revenue growth (TTM) | 599% (better) | 12.0% |
| Revenue growth, 5Y average | 74.5% (better) | 2.0% |
| Profitability | ||
| Gross margin | 86.1% | – |
| Operating margin | – | −94.1% |
| Net margin | −47.8% (better) | −113% |
| FCF margin | −37.1% (better) | −143% |
| Return on equity | – | −138% |
| Financial health | ||
| Interest coverage | – | −3.9× |
| Current ratio | 2.43 | 2.86 (better) |
| Altman Z-score | – | −3.83 |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 0.30% | 64.2% |
| Held by insiders | 37.3% | 7.6% |
| Insider net buying, 12 months | $37.5M (better) | $9.6K |
| Short interest, % of float | – | 16.7% |
Go deeper
- MESO stock overview
- MESO income statement
- MESO valuation and score
- RGNX stock overview
- RGNX income statement
- RGNX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.